China’s NMPA Approves Taletrectinib in Previously Treated ROS1+ Advanced NSCLC
China’s NMPA has approved taletrectinib for locally advanced or metastatic ROS1-positive non–small cell lung cancer after a previous ROS1 TKI.
Related Articles
Combination Regimens Make Their Mark in Frontline HCC
In a Peer Exchange, HCC experts discussed how new data from the HIMALAYA, LEAP-012, EMERALD-1, and IMbrave050 trials could be used to optimize treatment.
CaDAnCe-101 study: preliminary efficacy and safety of the BTK degrader BGB-16673 in R/R indolent NHL
Chan Cheah, MBBS, FRACP, FRCPA, DMSc, Linear Clinical Research and Sir Charles Gairdner Hospital, Perth, Australia, comments on the preliminary efficacy and safety of the…
Current barriers in using AI to diagnose skin cancers
Harald Kittler, MD, Medical University of Vienna, Vienna, Austria, comments on the current challenges in the clinical implementation of artificial intelligence (AI) for the diagnosis…
What We Can Learn About Patient Safety While Driving to Work
This Viewpoint discusses strategies used with driving that can be applied to health care to promote consistent and predictable physician and patient actions.
Prophylactic Tocilizumab Reduces Toxicity, Boosts Efficacy in Immune Checkpoint Inhibitor–Treated Melanoma
Matthew Hadfield, DO, discusses findings from a phase 2 study that used tocilizumab to reduce toxicities with immune checkpoint inhibitors in melanoma.
Modakafusp Alfa Demonstrates Activity in Rel/Ref Multiple Myeloma – Oncology Nurse Advisor
Both dose levels of modakafusp alfa “resulted in good response rates with similar safety profiles,” according to researchers.
Leonard and Norma Klorfine Endowed Chair for Clinical Research awarded to Dr. Geoffrey Hill
Geoffrey Hill, MD, FRACP, FRCPA, was recently announced as the recipient of the Leonard and Norma Klorfine Endowed Chair for Clinical Research at Fred Hutch…
